New drug cocktail aims to tackle tough pancreatic cancer
NCT ID NCT06646055
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental drugs, AK112 and cadonilimab, combined with standard chemotherapy as a first treatment for people with metastatic pancreatic cancer. About 110 participants will receive the combination to see if it is safe and helps shrink tumors. The goal is to find a better option for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK112, cadonilimab, nab-paclitaxel, gemcitabine
What this could lead to
If successful, this combination could offer a new first-line treatment option for metastatic pancreatic cancer, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 110 participants, so results may not apply broadly. The added drugs may increase side effects, and the treatment may not work better than standard chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology.
Wuhan, Hubei, China